Abstract: A method of correcting an axial position of a workpiece support (1) used for removing material from a dental workpiece (2) which is held by the workpiece support (1) and is rotated together with the workpiece support (1) about a drive rotation axis (3) when material is being removed. The workpiece support (1) has at least two workpiece support parts (4, 5, 6) which can be separated from each other and connected to each other. One of the workpiece support parts (4, 5) has at least one compensation region (7) with a material projection (8) for introducing a compensation surface (9) by removing material, and the other workpiece support part (6) has a seating surface (10) for connecting to the compensation surface (9) in a form fitting manner.

Abstract: The invention relates to a milling machine for producing a dental component, such as a crown or an abutment for example, from a blank. The milling machine includes a stop and a holder for the blank. The invention is characterized in that the holder is designed such that the holder can be surrounded by a mounting, which surrounds the holder, of the blank, and the surrounding mounting of the blank can be brought into contact with the stop for positioning purposes. The invention further relates to a corresponding blank.

Abstract: A method of correcting an axial position of a workpiece support (1) used for removing material from a dental workpiece (2) which is held by the workpiece support (1) and is rotated together with the workpiece support (1) about a drive rotation axis (3) when material is being removed. The workpiece support (1) has at least two workpiece support parts (4, 5, 6) which can be separated from each other and connected to each other. One of the workpiece support parts (4, 5) has at least one compensation region (7) with a material projection (8) for introducing a compensation surface (9) by removing material, and the other workpiece support part (6) has a seating surface (10) for connecting to the compensation surface (9) in a form fitting manner.

Abstract: The invention relates to a milling machine for producing a dental component, such as a crown or an abutment for example, from a blank. The milling machine includes a stop and a holder for the blank. The invention is characterized in that the holder is designed such that the holder can be surrounded by a mounting, which surrounds the holder, of the blank, and the surrounding mounting of the blank can be brought into contact with the stop for positioning purposes. The invention further relates to a corresponding blank.

Abstract: A workpiece support (1) for removing material from a dental workpiece (2) which is held by the workpiece support (1) and is rotated together with the workpiece support (1) about a drive rotation axis (3) when material is being removed. The workpiece support (1) has at least two workpiece support parts (4, 5, 6) which can be separated from each other and connected to each other. One of the workpiece support parts (4, 5) has at least one compensation region (7) with a material projection (8) for introducing a compensation surface (9) by removing material, and the other workpiece support part (6) has a seating surface (10) for connecting to the compensation surface (9) in a formfitting manner.

Abstract: or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally compris

Abstract: or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile, or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4; wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate; R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring; or R1 and R2 form a 3-10 membered carbon ring optionally comprising

Abstract: The present invention relates to novel compounds of the general formula (I) wherein R1, R2, R3 and R4 are as defined, having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).

Abstract: The present invention relates to novel xanthine compounds of the general formula (I) wherein R1, R2, R3 and R4 are as defined, having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).

Abstract: The present invention relates to compounds of formula I wherein R1 represents a group R5O— in which R5 represents a C3-7alkyl group substituted by one or more fluoro or R5 represents a C3-7alkylsulphonyl group which is optionally substituted by one or more fluoro; R2 represents a C1-4alkyl group, hydroxy, fluoro, chloro or cyano wherein each R2 is independently selected when n is >1; R3 represents a) cyclohexyl optionally substituted by one or more of the following: hydroxy, fluoro, amino, mono or diC1-3alkylamino, carboxy or a C1-4alkoxycarbonyl group b) piperidino substituted by one or more hydroxy c) unsubstituted piperidino but only when one of the following applies: R4 represents cyano or R1 represents 3-fluoropropylsulphonyloxy or R1 represents 3,3,3-trifluoropropoxy or R1 represents 3-fluoropropoxy or R2 is methyl d) phenyl substituted by one or more of the following: hydroxy, halo or a C1-4alkyl group e) pyridyl substituted by a C1-4alkyl group or f) a C4-9alkyl group; R4 represents cyano or me

Abstract: The present invention relates to novel imidazole compounds having a positive allosteric GABAB receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).

Abstract: Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.

Abstract: Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.

Abstract: Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.

Abstract: The present invention concerns novel aromatic long chain alkyl ethers and thioethers of the formula, ##STR1## wherein R.sub.1 is a hydrocarbon group,R.sub.2, r.sub.3, r.sub.4 and R.sub.5, are each hydrogen or alkyl,w and z are integers,X is an ether or thioether bridge, andR.sub.6 is an aromatic radical.The compounds are useful as insecticides and acaricides.

Abstract: The present invention concerns novel aromatic long chain alkenyl ethers and thioethers of the formula: ##EQU1## wherein R.sub.1 is a hydrocarbon group,R.sub.2, r.sub.3 and R.sub.4 are each H or alkyl,R.sub.6 is an aromatic radical,Z is a divalent hydrocarbon group,Y is o or s, andw and n are zero or integers.The compounds are useful insecticides and acaricides.

Abstract: The present invention concerns novel compounds of the formula: ##EQU1## wherein R.sub.1 to R.sub.9 have various significances including e.g. alkyl, X and Y include O and S and s, v, w and z are O or whole numbers and Ar.sub.1 is a formyl phenyl radical.The compounds possess insecticidal properties.

Abstract: The present invention concerns the use of the compounds of the formula: ##EQU1## wherein R.sub.1 to R.sub.9 have various significances including e.g. alkyl, X and Y include O and S, and s, v, w and z are O or whole numbers and Ar.sub.1 is substituted phenyl, as insecticides, and insecticidal compositions containing said compounds as active agent.

Abstract: The present invention concerns unsaturated ethers or thioethers of the formula: ##EQU1## wherein R.sub.1 is an aliphatic or alicyclic hydrocarbon, R.sub.2 and R.sub.3 are H or alkyl, Y is cyano, amido, a ketone or an acid ester, ##EQU2## is an ether, thioether or a saturated or unsaturated c--c bond and n is an integer, which exhibit insecticidal properties.

Abstract: The present invention concerns unsaturated ethers or thioethers of the formula: ##EQU1## wherein R.sub.1 is an aliphatic or alicyclic hydrocarbon, R.sub.2 and R.sub.3 are H or alkyl, Y is cyano, amido, a ketone or an acid ester, ##EQU2## is an ether, thioether or a saturated or unsaturated c--c bond and n is an integer, which exhibit insecticidal properties.